USPTO Examiner ABBAS ABDULRAHMAN MUSTAFA - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19194125ORGANIC NANOCOMPOSITE COATING FOR PHARMACEUTICAL APPLICATIONS AND A METHOD OF FABRICATION THEREOFApril 2025August 2025Allow301NoNo
18308557NANOLIPOSOMES FOR SUSTAINED DELIVERY OF TACROLIMUS FOR TREATMENT OF ANTERIOR SEGMENT EYE DISEASESApril 2023October 2025Allow3010NoNo
18146787PECTIN BASED FIRMING SYSTEM FOR ANTIAGING SKIN CARE AND MAKEUPSDecember 2022October 2024Allow2120NoNo
18064470HAIR STYLING COMPOSITIONSDecember 2022April 2024Allow1610NoNo
18070863SKIN CARE COMPOSITION AND METHOD FOR TREATING POST-ACNE MARKSNovember 2022April 2024Allow1710NoNo
18000154LIPOSOME CONTAINING ETHYLENEDIAMINE TETRAACETIC ACID OR SALT THEREOF AND ERIBULIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOFNovember 2022December 2025Abandon3610NoNo
17992662STIMULI RESPONSIVE BLOCK COPOLYMERSNovember 2022April 2025Allow2911NoNo
17926663SYNERGISTIC ANTI-VIRAL PHARMACEUTICAL COMPOSITION CONTAINING TARGETING NANOPARTICLESNovember 2022February 2026Allow3910YesNo
17985927Hair growth essence and its preparation methodNovember 2022May 2024Abandon1811NoNo
17979312COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASENovember 2022October 2024Abandon2420NoNo
17977139Personal Care CompositionsOctober 2022January 2024Allow1510YesNo
18049244METHOD FOR MAKING MODIFIED POLYVINYL ALCOHOL EMBOLIC MICROSPHEREOctober 2022December 2023Allow1310NoNo
17940746METFORMIN TABLET FOR RELIEVING PAIN AND REDUCING INFLAMMATION AND MANUFACTURING METHOD THEREOFSeptember 2022August 2024Allow2411YesNo
17876611Implantable Medical Device for the Delivery of BisphosphonateJuly 2022July 2024Abandon2311NoNo
17811446PARTIALLY PRE-GELATINIZED CASSAVA STARCH AS PHARMACEUTICAL EXCIPIENTJuly 2022September 2024Allow2620YesNo
17791815NANOBOWL-SUPPORTED DRUG-LOADED LIPOSOME, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFJuly 2022December 2025Allow4120NoNo
17858484ORODISPERSIBLE FORMULATIONSJuly 2022April 2025Abandon3410NoNo
17808305HAIR-STRAIGHTENING COMPOSITIONSJune 2022August 2024Abandon2520NoNo
17838360MULTI-FUNCTION HAIR CARE COMPOSITIONJune 2022April 2024Allow2220NoNo
17783744ESKETAMINE FORMULATIONS AND METHODS FOR PREPARATION AND STORAGEJune 2022February 2026Allow4411NoNo
17756619AMLODIPINE MESYLATE MONOHYDRATE PREPARATION METHOD THEREFOR AND USE THEREOFMay 2022May 2025Allow3610NoNo
17777800VETERINARY FORMULATIONS COMPRISING RAPAMYCIN AND METHODS OF USING THE SAME FOR TREATING ANIMAL DISEASEMay 2022December 2025Allow4320YesNo
17742418LIPOSOME COMPOSITION AND PREPARATION METHOD THEREOFMay 2022October 2025Allow4110NoNo
17697362Method of Combining Pigmentation Agents in Hair Dyeing and Related Products for Generating Cool TonesMarch 2022January 2024Abandon2210NoNo
17633723FORMULATIONFebruary 2022March 2025Abandon3710NoNo
17630681LIPOSOMES AND USES THEREOFJanuary 2022July 2025Abandon4110NoNo
17630451PIGMENTS CONTAINING CELLULOSEJanuary 2022February 2025Abandon3610NoNo
17619019SYNERGISTIC FUNGICIDAL COMPOSITIONDecember 2021July 2025Allow4320NoNo
17616951Engineered nono-lyposomes for a targeted therapy of atherosclerosis and preparation process thereofDecember 2021September 2025Abandon4611NoNo
17539470METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND PULMONARY ARTERIAL HYPERTENSIONDecember 2021June 2025Allow4241YesNo
17614881INJECTABLE COMPOSITION CONTAINING PRODRUG OF CASPASE INHIBITORS, AND PREPARATION METHOD THEREFORNovember 2021November 2024Allow3510NoNo
17526833DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONSNovember 2021July 2024Abandon3201NoNo
17280379DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTSOctober 2021October 2025Abandon5520NoNo
17606657SHAPE MEMORY POLYMER HYDROGELS FOR WOUND HEALINGOctober 2021October 2025Allow4821NoNo
17604330BIODEGRADABLE NASAL SPLINTOctober 2021November 2024Abandon3710NoNo
17603815TABLET AND METHOD FOR PRODUCING TABLETOctober 2021October 2025Allow4821NoNo
17600203Siremadlin SuccinateSeptember 2021November 2024Abandon3810NoNo
17598691Covalent Modification and Controlled Delivery of Mu Opioid Receptor AntagonistsSeptember 2021June 2025Allow4420YesNo
17598797METHODS OF IMPROVING PHARMACEUTICAL SUBSTANCE SOLUBILIZATION AND PRODUCTS THEREOFSeptember 2021January 2025Allow4010NoNo
17438969PROCESS FOR SPRAY DRYING A GLP-1 PEPTIDESeptember 2021September 2024Allow3610NoNo
17435905BENZOAZEPINE COMPOUND-CONTAINING FREEZE-DRIED COMPOSITIONSeptember 2021February 2025Abandon4210NoNo
17431285SURGICAL GLUES BASED ON MONOMERS COMPRISING A PHOSPHATE FUNCTIONAugust 2021February 2025Allow4210NoNo
17431399SATIETY INDUCING FOOD PRODUCTS AND PREPARATION THEREOFAugust 2021April 2025Allow4421YesNo
17431303METHOD FOR SUPPRESSING COLD FLOW OF ACRYLIC PATCHAugust 2021April 2025Abandon4420NoNo
17430943Process for the preparation of microcapsulesAugust 2021September 2024Allow3810NoNo
17425057ELECTROSPUN NANOFIBER-BASED DRESSINGS AND METHODS OF MANUFACTURE AND USE THEREOFJuly 2021November 2025Abandon5121NoNo
17425253DENTAL FLOSS FOR PREVENTING OR TREATING DENTAL CARIES AND PERIODONTAL DISEASEJuly 2021May 2025Abandon4620NoNo
17377103COMPOSITIONS AND METHODS FOR PREVENTION OF VIRAL INFECTIONS AND ASSOCIATED DISEASESJuly 2021August 2024Abandon3701NoNo
17419397ORAL ARTICLES AND METHODS OF USEJune 2021October 2025Allow5230NoNo
17341812ANTIMICROBIAL and ANTI-INFLAMMATORY COMPOSITIONJune 2021September 2025Abandon5141NoNo
17296927CLEANSING COMPOSITIONMay 2021December 2025Abandon5530NoNo
17296244BIODEGRADEABLE IMPLANT COMPRISING COATED METAL ALLOY PRODUCTMay 2021April 2025Allow4711NoNo
17245538SYNERGY FOR INCREASING ENERGY EXPENDITURE AND INSULIN SENSITIVITYApril 2021September 2025Abandon5321NoNo
17290499Cosmetic Composition For Sustaining LusterApril 2021June 2025Allow4930YesNo
17284335COATING COMPOSITION FOR MEDICAL IMPLANTSApril 2021September 2024Abandon4101NoNo
17284171COMPOSITIONS AND METHODS FOR ADMINISTERING ANESTHETICSApril 2021October 2025Abandon5531NoNo
17250747POLYMER IMPLANTSFebruary 2021December 2024Allow4520YesNo
17259499BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAMEJanuary 2021September 2024Allow4520YesYes
17054037SAFENERNovember 2020July 2025Abandon5640YesNo
16322656COSMETIC TENSIONING COMPOSITIONFebruary 2019July 2025Abandon6080YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ABBAS, ABDULRAHMAN MUSTAFA.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ABBAS, ABDULRAHMAN MUSTAFA - Prosecution Strategy Guide

Executive Summary

Examiner ABBAS, ABDULRAHMAN MUSTAFA works in Art Unit 1612 and has examined 33 patent applications in our dataset. With an allowance rate of 48.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner ABBAS, ABDULRAHMAN MUSTAFA's allowance rate of 48.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ABBAS, ABDULRAHMAN MUSTAFA receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ABBAS, ABDULRAHMAN MUSTAFA is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +35.0% benefit to allowance rate for applications examined by ABBAS, ABDULRAHMAN MUSTAFA. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 41.7% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.